{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inhalational+Anthrax",
    "query": {
      "condition": "Inhalational Anthrax"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T04:49:00.138Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01932437",
      "title": "Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Inhalational Anthrax"
      ],
      "interventions": [
        {
          "name": "ETI-204",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Elusys Therapeutics",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2013-07-26",
      "completion_date": "2014-07-03",
      "has_results": true,
      "last_update_posted_date": "2019-05-06",
      "last_synced_at": "2026-07-24T04:49:00.138Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01932437"
    },
    {
      "nct_id": "NCT00448253",
      "title": "Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Symptoms of Inhalational Anthrax"
      ],
      "interventions": [
        {
          "name": "NP-015",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 92,
      "start_date": "2007-07",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2024-03-15",
      "last_synced_at": "2026-07-24T04:49:00.138Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00448253"
    },
    {
      "nct_id": "NCT01932242",
      "title": "Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Inhalational Anthrax"
      ],
      "interventions": [
        {
          "name": "ETI-204",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Elusys Therapeutics",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2013-07-23",
      "completion_date": "2014-04-19",
      "has_results": true,
      "last_update_posted_date": "2019-05-14",
      "last_synced_at": "2026-07-24T04:49:00.138Z",
      "location_count": 2,
      "location_summary": "Overland Park, Kansas • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01932242"
    },
    {
      "nct_id": "NCT01929226",
      "title": "Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Inhalational Anthrax"
      ],
      "interventions": [
        {
          "name": "ETI-204",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Elusys Therapeutics",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2013-07-09",
      "completion_date": "2013-11-29",
      "has_results": true,
      "last_update_posted_date": "2019-04-08",
      "last_synced_at": "2026-07-24T04:49:00.138Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01929226"
    },
    {
      "nct_id": "NCT01952444",
      "title": "Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Inhalational Anthrax"
      ],
      "interventions": [
        {
          "name": "ETI-204",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ciprofloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Elusys Therapeutics",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 40,
      "start_date": "2013-10-29",
      "completion_date": "2014-04-09",
      "has_results": true,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-07-24T04:49:00.138Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01952444"
    },
    {
      "nct_id": "NCT00138411",
      "title": "Monoclonal Antibody for Treatment of Inhalation Anthrax",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bacillus Anthracis (Anthrax)"
      ],
      "interventions": [
        {
          "name": "Ciprofloxacin 500 mg",
          "type": "DRUG"
        },
        {
          "name": "ETI-204 (Anthim)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 36,
      "start_date": "2005-10",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-07-24T04:49:00.138Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00138411"
    }
  ]
}